ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Financial performance, 2002-14 7
Chugai: PharmaVitae forecasts at a glance 8
Strategic insight 9
The Roche/Genentech/Chugai alliance 9
Partnership grants Chugai access to leading mAb portfolio 9
Reliance on mAb portfolio 9
Chugai dominates the Japanese mAb landscape 10
Roche/Genentech portfolio to contribute majority of Chugai's forecast growth 11
Chugai is good strategic fit for Roche's Japanese market expansion 13
SWOT analysis 14
Strengths 14
Weaknesses 15
Opportunities 16
Threats 16
Table of Contents 18
Table of figures 20
Chapter 3 Quarterly news update 21
Product developments 21
Deals and alliances 22
Product deals 22
Technology deals 22
M&A activity 23
Company announcements 23
Future product milestones 24
Chapter 4 Company introduction 25
Key findings 25
Background 26
Key corporate developments 26
M&A history 27
Acquisition of GenProbe in December 1989 27
Consolidation into the Roche group in October 2002 27
Divestments since the Roche merger have promoted Rx focus 28
Current corporate structure 29
Chapter 5 Company sales 30
Key findings 30
Prescription pharmaceutical sales and growth rate analysis, 2002-14 31
Product analysis 33
Product analysis, 2002-08 34
Product analysis, 2008-14 38
Therapy area analysis 42
Geographic analysis 45
Launch/core/expiry analysis 48
Explanation of launch/core/expiry analysis 48
Launch analysis, 2008-14 49
Core analysis, 2008-14 51
Expiry analysis, 2008-14 53
Launch/core/expiry configuration, 2008-14 54
Molecule type analysis 55
Externalization analysis 58
Chapter 6 Company financials 61
Key findings 61
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 62
Operating costs and profit analysis 64
Operating costs and profit analysis, 2002-08 65
Operating cost ratio and profit margin analysis, 2002-08 67
Operating cost ratio and profit margin analysis, 2008-14 68
Operating costs and profit analysis, 2008-14 69
Chapter 7 Key products and competitors 70
Key findings 70
Overview 71
Oncology 72
Avastin 72
Overview 72
Sales forecast 73
First-to-market VEGF inhibitor 73
Indication broadening expected to drive sales 73
Key competitors 73
Herceptin 75
Overview 75
Sales forecast 76
What is Herceptin? 76
Key competition from Tykerb in the long term 77
Rituxan 78
Overview 78
Sales forecast 79
What is Rituxan? 79
Indication-broadening to promote sustained sales expansion 79
Rituxan currently faces little competition and steady sales are anticipated 80
Neutrogin 81
Overview 81
Sales forecast 82
Internally developed Neutrogin is central to Chugai's historical growth 82
Biosimilar threat to EU market 83
Tarceva 84
Overview 84
Sales forecast 85
What is Tarceva? 85
Key competitors 85
Hematology 87
Epogin 87
Overview 87
Sales forecast 88
Kirin's Espo and follow-on Nesp pose key competition 88
Mircera to become Epogin's follow-on product 89
Safety concerns around EPO use in some cancer patients 89
Biosimilar EPOs available in the 5EU 89
R-744/Mircera 90
Overview 90
Sales forecast 91
R-744/Mircera provides follow-on to Epogin 91
Kirin's Nesp, a follow-on to Espo, will provide key competition 91
Immunology & inflammation 93
Actemra 93
Overview 93
Sales forecast 94
What is Actemra? 94
Key competitors 94
Product positioning 94
Infectious disease 96
Tamiflu 96
Overview 96
Sales forecast 97
Stockpiling represents majority of historical revenue 97
Pegasys 98
Overview 98
Sales forecast 99
The advantages of pegylation 99
Schering-Plough's Peg-Intron is the market leader in Japan 99
Copegus launch to facilitate growth over forecast period 100
Pipeline competitors present long-term threat 100
Genitourinary 102
Evista 102
Overview 102
Sales forecast 103
Evista is the only SERM osteoporosis treatment in Japan 103
Japanese guidelines rate Evista as a class A osteoporosis treatment 103
R484/Boniva and ED-71 launch will boost Chugai's osteoporosis franchise 103
Musculoskeletal 105
R-484/Boniva 105
Overview 105
Sales forecast 106
Chapter 8 Appendix 107
R&D pipeline 107
References 108
Datamonitor (2009), AstraZeneca plc: PharmaVitae Profile, March 2009, CSHC1408 108
Abbreviations 109
Exchange rates 110
About Datamonitor 111
About Datamonitor Healthcare 111
Datamonitor consulting 111
Disclaimer 113
List of Tables
Table 1: Chugai - PharmaVitae forecasts at a glance 8
Table 2: Chugai key product developments, 2009 21
Table 3: Chugai product deals and alliances, 2009 22
Table 4: Chugai technology deals and alliances, 2009 22
Table 5: Chugai M&A activity, 2009 23
Table 6: Chugai company announcements, 2009 23
Table 7: Chugai future product milestones, 2009-11 24
Table 8: Chugai product portfolio overview ($m), 2002-08 34
Table 9: Chugai product portfolio overview ($m), 2008-14 38
Table 10: Chugai prescription pharmaceutical sales by therapy area ($m), 2008-14 43
Table 11: Chugai prescription pharmaceutical sales by geographic region ($m), 2008-14 46
Table 12: Chugai launch portfolio overview ($m), 2008-14 49
Table 13: Chugai core portfolio overview ($m), 2008-14 51
Table 14: Chugai expiry portfolio overview ($m), 2008-14 53
Table 15: Chugai prescription pharmaceutical sales by molecule type ($m), 2008-14 56
Table 16: Chugai prescription pharmaceutical sales by source ($m), 2008-14 59
Table 17: Total Chugai sales by business unit ($m), 2002-08 62
Table 18: Chugai operating revenue/cost analysis ($m), 2002-08 65
Table 19: Chugai operating cost ratio analysis (% of total revenues), 2002-08 67
Table 20: Chugai operating cost ratio analysis (% of total revenues), 2008-14 68
Table 21: Chugai operating revenue/cost analysis ($m), 2008-14 69
Table 22: Key products overview 71
Table 23: Avastin: overview 72
Table 24: Avastin: sales forecast ($m), 2008-14 73
Table 25: Herceptin: overview 75
Table 26: Herceptin: sales forecast ($m), 2008-14 76
Table 27: Rituxan: overview 78
Table 28: Rituxan: sales forecast ($m), 2008-14 79
Table 29: Neutrogin: overview 81
Table 30: Neutrogin: sales forecast ($m), 2008-14 82
Table 31: Tarceva: overview 84
Table 32: Tarceva: sales forecast ($m), 2008-14 85
Table 33: Epogin: overview 87
Table 34: Epogin: sales forecast ($m), 2008-14 88
Table 35: R-744/Mircera: overview 90
Table 36: R-744/Mircera: sales forecast ($m), 2008-14 91
Table 37: Actemra: overview 93
Table 38: Actemra: sales forecast ($m), 2008-14 94
Table 39: Tamiflu: overview 96
Table 40: Tamiflu: sales forecast ($m), 2008-14 97
Table 41: Stockpiling and prescription Tamiflu sales ($m), 2003-08 97
Table 42: Pegasys: overview 98
Table 43: Pegasys: sales forecast ($m), 2008-14 99
Table 44: Evista: overview 102
Table 45: Evista: sales forecast ($m), 2008-14 103
Table 46: R-484/Boniva: overview 105
Table 47: R-484/Bomiva: sales forecast ($m), 2008-14 106
Table 48: Chugai's R&D pipeline (Phase I-registration) 107
Table 49: Exchange rates, 2009 110
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Chugai's financial performance ($m), 2002-14 7
Figure 4: Roche/Genentech/Chugai alliance 9
Figure 5: Chugai dependency on mAb portfolio as a % of total revenues, 2002-14 10
Figure 6: Total Japanese mAb market sales by company, 2002-14 ($m) 11
Figure 7: Chugai pharmaceutical sales growth by source company, 2002-14 ($m) 12
Figure 8: Chugai SWOT analysis 14
Figure 9: Current corporate structure 29
Figure 10: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 31
Figure 11: Key product sales ($m), 2002-14 33
Figure 12: Chugai key sales growth drivers and resistors ($m), 2002-08 35
Figure 13: Chugai key sales growth drivers and resistors ($m), 2008-14 39
Figure 14: Chugai prescription pharmaceutical sales by therapy area ($m), 2002-14 42
Figure 15: Chugai prescription pharmaceutical sales by geographic region ($m), 2002-14 45
Figure 16: Chugai launch/core/expiry configuration ($m), 2008-14 54
Figure 17: Chugai prescription pharmaceutical sales by molecule type ($m), 2002-14 55
Figure 18: Chugai prescription pharmaceutical sales by source ($m), 2002-14 58
Figure 19: Chugai operating revenue/cost analysis ($m), 2002-14 64
